KYTX (Kyverna Therapeutics) Short-Term Debt to Capital
The Kyverna Therapeutics (KYTX) price chart on the GURU.Markets platform reflects the asset's dynamics, with a value of 0.01. The brand is recognized as a leader in developing CAR-T therapies to combat autoimmune pathologies. Its growth strategy relies on academic partnerships and the expansion of its own development portfolio without mergers. While high-tech cell synthesis is automated, tissue collection remains the prerogative of qualified medical professionals.
Analytical breakdowns for Kyverna Therapeutics
- stock quotes and analyst forecast:
- business market valuation indicators:
- book capitalization information:
- company liabilities and liquidity data:
Total Debt to Capital Kyverna Therapeutics|KYTX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Kyverna Therapeutics, Inc.|KYTX - Aggregate Debt Obligations|Debts to Book Capitalization Kyverna Therapeutics Inc.|KYTX - Long-Term Debt Volume|Company Short-Term Debt Kyverna Therapeutics|Quick Liquidity kyvernatx.com
- company profitability and valuation multiples indicators:
Fundamental valuation:Kyverna
For the biotech sector company Kyverna Therapeutics (KYTX), which focuses on scalable cell therapy, the short-term debt-to-equity ratio reflects the balance between expansion and financial stability. This metric is calculated as the ratio of current liabilities with a maturity of up to one year to total equity. The current value of 0.01 demonstrates the company's degree of reliance on rapid refinancing. A decrease in this ratio confirms solvency and minimizes bankruptcy risk during the platform's development.
Main competitors
Short-Term Debt to Capital ARGX|BNTX (BioNTech Pharma) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ABVX (Abivax Pharma)|Short-Term Debt to Capital admabiologics.com ADMA|PTGX - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital IMVT (Immunovant Inc)|Kiniksa Pharmaceuticals Ltd (KNSA) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Grifols Biemat|ADPT (Adaptive Biotechnologies) - Short-Term Debt to Capital|Short-Term Debt to Capital celldex.com|Short-Term Debt to Equity Ratio AUPH (Aurinia Pharmaceuticals Inc.)|BCRX (BioCryst Pharmaceuticals, Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VERA (Vera Pharma)|Short-Term Debt to Capital Coefficient Dianthus Corp (DNTH)|PHVS - Short-Term Debt to Equity|AbCellera Biologics Inc (ABCL) - Short-Term Debt to Equity Ratio|Tourmaline Bio (TRML) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Precigen Inc|Short-Term Debt to Equity Ratio PHAR|Short-Term Debt to Capital Nektar Corp|Short-Term Debt to Equity Upstream Bio Inc (UPB)|zenasbio.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital IMNM (Immunome)|Gossamer Bio Inc (GOSS) - Current Liabilities to Capital|KALV - Short-Term Debt to Equity|SEPN - Short-Term Debt to Capital|PVLA (Pieris Pharmaceuticals) - Short-Term Debt to Equity Ratio|Current Liabilities to Capital savarapharma.com (SVRA)|Short-Term Debt to Equity Ratio RIGL|Short-Term Debt to Equity ANAB|Short-Term Debt to Capital ATXS|ENGN - Current Liabilities to Capital|Short-Term Debt to Equity RAPT Therapeutics RAPT|Ratio of Short-Term Indebtedness to Capital JBIO|ACRS - Short-Term Debt to Equity|TLSA (Tiziana Life Sciences Ltd.) - Short-Term Debt to Capital Ratio|CABA: Short-Term Debt to Capital|Ventyx Biosciences, Inc (VTYX) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio THTX|AVTX: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio ELDN (Eledon Pharmaceuticals, Inc.)|Short-Term Loans to Capital Ratio AGEN|Short-Term Debt to Capital CLYM (Climb Bio, Inc.)|Ratio of Short-Term Indebtedness to Capital ZURA|aTyr Pharma, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital Adagene|ikenaoncology.com (IMA) - Short-Term Debt to Equity|Shattuck Labs - Ratio of Short-Term Indebtedness to Capital|EQ (Equillium Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital Connect Pharma|Short-Term Debt to Equity Immunic, Inc. (IMUX)|ATRA: Current Liabilities to Equity|Short-Term Debt to Capital IFRX (InflaRx)|X4 Pharmaceuticals Inc. (XFOR) - Current Liabilities to Capital|ACET: Short-Term Debt to Equity Ratio|CELU - Short-Term Debt to Capital|INMB (INmune Bio, Inc.) - Short-Term Debt to Equity Ratio|BRNS: Short-Term Loans to Capital Ratio|KZR (Kezar Life Sciences, Inc.) - Short-Term Debt to Capital|SAB Biotherapeutics Inc. (SABS) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital AKTX|Short-Term Debt to Equity Ratio enlivex.com ENLV|Short-Term Debt to Equity Q32 Bio QTTB|Short-Term Debt to Capital Coefficient geovax.com (GOVX)|EDSA - Short-Term Debt to Equity|IBIO - Short-Term Debt to Capital|CARM (carismatx.com) - Short-Term Debt to Equity Ratio|Current Liabilities to Capital XTL Bio (XTLB)|Short-Term Debt to Equity Ratio BOLT|HCWB (HCW Biologics Inc) - Short-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio APVO (Aptevo Therapeutics)|aimimmuno.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Equity Aditxt, Inc. ADTX|GRI (GRI Bio Corporation) - Current Liabilities to Equity|XORTX Therapeutics Inc. - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital HIND (reshapelifesciences.com)|REVB: Short-Term Debt to Capital|Indaptus Therapeutics Inc (INDP) - Short-Term Debt to Capital|Short-Term Debt to Equity Scinai|CALI: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Affimed (AFMD)|Short-Term Debt to Equity Ratio allakos.com ALLK|Short-Term Debt to Capital HOOK (HOOKIPA Pharma)|Short-Term Debt to Capital IGM Biosciences Inc. IGMS|ITOS: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital OCEA (Ocean Biomedical Corp)|TCBP: Short-Term Debt to Capital|THRD - Short-Term Debt to Capital Coefficient